Mandos Health is a biopharmaceutical company committed to furthering the development of VTS-270 for Niemann-Pick Type C, an ultra-rare genetic disease that affects the body’s ability to metabolize cholesterol and lipids within cells. Niemann-Pick Type C disease can affect the brain, nerves, liver, spleen, bone marrow, and lungs and there are currently no FDA-approved treatments.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.